Pfizer Update on COVID-19 Vaccine Distribution

News
KZOO-Vials-in-Tray-2-(1)_790X500.jpg
KZOO-Vials-in-Tray-2-(1)_1000X450.jpg

Pfizer Update on COVID-19 Vaccine Distribution

Statement from Pfizer Regarding COVID-19 Vaccine Production and Distribution.

READ THE STATEMENT

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

The Colleague & Dad Who Keeps Our Medicines and Vaccines on Ice

News
James_Headshot_790X500.jpg
James_Headshot_1000X450.jpg

The Colleague & Dad Who Keeps Our Medicines and Vaccines on Ice

Meet James

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

THE ANTIGEN: #COVID19 PODCAST

Podcasts
the_antigen_image_380x700.png
the_antigen_image_1000x450.jpg

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

Listen & subscribe here

VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Latest News

Pfizer’s XALKORI® (crizotinib) Approved by FDA…

XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI ® (crizotinib) for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The safety and efficacy of…
Read more